SCHEDULE 13G/A: Harraden Circle Entities Reduce Stake in Aspire Biopharma Holdings, File Exit Schedule 13G

Harraden Circle Investments and affiliated entities, including Frederick V. Fortmiller, Jr., have significantly reduced their beneficial ownership in Aspire Biopharma Holdings, Inc. to below 5%, triggering an exit filing with the SEC.

Summary

• Harraden Circle Investments, LLC and its affiliated entities, along with Frederick V. Fortmiller, Jr., have filed an Amendment No. 1 to Schedule 13G for Aspire Biopharma Holdings, Inc.
• The filing indicates that the Reporting Persons have ceased to be the beneficial owners of more than five percent of the outstanding Class A Common Stock of Aspire Biopharma Holdings, Inc.
• This amendment serves as an exit filing for the Reporting Persons, meaning they are no longer required to report their holdings under Schedule 13G.
• As of March 31, 2025, Harraden Circle Investments, LLC and Frederick V. Fortmiller, Jr. beneficially own 150,000 shares, representing 0.31% of the Class A Common Stock.
• Other affiliated entities, such as Harraden Circle Investors GP, LP and Harraden Circle Investors GP, LLC, report shared voting and dispositive power over 133,173 shares (0.27%).
• Harraden Circle Investors, LP holds 95,673 shares (0.2%), and Harraden Circle Special Opportunities, LP holds 37,500 shares (0.08%).
• Harraden Circle Strategic Investments, LP reports 0 shares and 0% beneficial ownership.
• The issuer, Aspire Biopharma Holdings, Inc., was formerly known as PowerUp Acquisition Corp.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative as a significant investor group has reduced its stake below the reporting threshold, which can be interpreted as a loss of confidence or a strategic exit, potentially impacting investor perception and stock performance.

Negatives

• A significant institutional investor group has reduced its stake in Aspire Biopharma Holdings, Inc. to below the 5% reporting threshold, which could be interpreted by the market as a decrease in confidence or a shift in investment strategy away from the company.

Risks

• The reduction in beneficial ownership by a significant investor group may lead to decreased institutional support or liquidity for the company's stock.

Future Outlook

The document does not provide any forward-looking statements or guidance from Aspire Biopharma Holdings, Inc. or the reporting persons regarding the company's future performance.

Management Comments

• Frederick V. Fortmiller, Jr., managing member of Harraden Circle Investments, LLC, certified that 'to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.'

Industry Context

This filing is a standard disclosure of a change in beneficial ownership by an institutional investor group. It does not provide specific insights into broader industry trends or competitive landscape for the biopharma sector.

Stakeholder Impact

• Shareholders: The reduction in a significant institutional stake might lead to concerns about the company's future prospects or a decrease in institutional support, potentially affecting share price stability.

Key Dates

Recommendation

Keywords

Aspire Biopharma Holdings, Harraden Circle Investments, Schedule 13G, Beneficial Ownership, Exit Filing, Class A Common Stock, SEC Filing, Institutional Investor, Frederick V. Fortmiller Jr.